Press release issued: 24 June 2024
Scientists at the University of Bristol have uncovered a new disease driving mechanism which they are aiming to target to help treat the development of atherosclerotic plaques.
The project to develop the new therapeutic, known as IMSET, is being led by Jason Johnson, Professor of Cardiovascular Pathology within Bristol Medical School. Following successful initial testing, Professor Johnson and his team have been awarded substantial funding through the beLAB1407 BRIDGE partnership to continue developing the new therapeutic.
Professor Johnson has been studying the condition known as Atherosclerosis, where the build-up of fatty deposits (atherosclerotic plaques) in arteries can lead to heart attacks, strokes, and peripheral arterial disease. Investigating how immune cells in the blood known as monocytes/macrophages contribute to the formation of these fatty plaques within arteries, the researchers have discovered that these cells can exist in different forms and there are particular macrophages which drive the development of the plaques.
Read the full University of Bristol news item
Further information
About Evotec SE
Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec provides high value pipeline co-creating partnerships and solutions to all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 5,000 highly qualified people. The Company’s sites in Europe and the USA offer highly synergistic technologies and services and operate as complementary clusters of excellence.
For additional information please go to http://www.evotec.com/ and follow us on X/Twitter @Evotec and LinkedIn
